We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.06B
AUM Growth
-$215M
Cap. Flow
-$288M
Cap. Flow %
-5.68%
Top 10 Hldgs %
52.55%
Holding
152
New
45
Increased
20
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$94.3M
2
PFE icon
Pfizer
PFE
+$87.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$79.4M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$38.7M
5
INSM icon
Insmed
INSM
+$35M

Top Sells

Rank Stock Value
1
WAY
Waystar Holding Corp
WAY
+$121M
2
ACH
Accendra Health
ACH
+$64.2M
3
ALHC icon
Alignment Healthcare
ALHC
+$40.8M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$38.8M
5
BCAX
Bicara Therapeutics
BCAX
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.22%
2 Real Estate 0.01%
3 Technology 0.01%
4 Consumer Discretionary 0.01%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
26
BioCryst Pharmaceuticals
BCRX
$2.35B
$38.9M 0.77%
5,189,665
-2,954,777
-36% -$23.8M
IRON icon
27
Disc Medicine
IRON
$2.86B
$38.8M 0.77%
782,333
+181,818
+30% +$10.1M
CNMD icon
28
CONMED
CNMD
$1.31B
$36.9M 0.73%
611,000
-964
-0.2% -$62.1K
NVST icon
29
Envista
NVST
$4.36B
$35M 0.69%
2,024,943
+1,006,528
+99% +$19.6M
INSM icon
30
Insmed
INSM
$23.6B
$34.9M 0.69%
+458,000
New +$35M
EMBC icon
31
Embecta
EMBC
$196M
$34.7M 0.68%
2,720,535
-550,000
-17% -$8.8M
CMRX
32
DELISTED
Chimerix, Inc.
CMRX
$32.1M 0.63%
3,771,342
– –
PHVS icon
33
Pharvaris
PHVS
$2.42B
$31.7M 0.63%
2,017,464
– –
CGEM icon
34
Cullinan Oncology
CGEM
$1.09B
$29.2M 0.58%
3,860,839
+481,440
+14% +$4.62M
INMD icon
35
InMode
INMD
$892M
$28M 0.55%
1,578,708
– –
PHR icon
36
Phreesia
PHR
$657M
$25.8M 0.51%
1,009,844
-261,988
-21% -$7.12M
VERA icon
37
Vera Therapeutics
VERA
$2.72B
$25.2M 0.5%
+1,050,000
New +$33.7M
LQDA icon
38
Liquidia Corp
LQDA
$7.06B
$23.8M 0.47%
+1,616,778
New +$23.6M
DAWN
39
DELISTED
Day One Biopharmaceuticals
DAWN
$23.5M 0.46%
2,960,740
+364,707
+14% +$3.93M
PRAX icon
40
Praxis Precision Medicines
PRAX
$8.8B
$23.5M 0.46%
+619,931
New +$38.7M
LNTH icon
41
Lantheus
LNTH
$6.91B
$23.4M 0.46%
240,218
– –
SVRA icon
42
Savara
SVRA
$1.12B
$22.1M 0.44%
7,964,000
– –
CGON icon
43
CG Oncology
CGON
$6.33B
$20.8M 0.41%
850,695
-898
-0.1% -$25.3K
ESTA icon
44
PUT
Establishment Labs
ESTA
$2.78B
$20.4M 0.4%
500,000
– –
CERT icon
45
Certara
CERT
$1.09B
$20M 0.4%
+2,022,616
New +$24.6M
IART icon
46
Integra LifeSciences
IART
$1.49B
$17.5M 0.35%
+794,865
New +$18.7M
BEAM icon
47
Beam Therapeutics
BEAM
$2.76B
$17.1M 0.34%
+877,809
New +$23M
KYMR icon
48
Kymera Therapeutics
KYMR
$9.44B
$16.2M 0.32%
593,000
– –
COGT icon
49
Cogent Biosciences
COGT
$6.65B
$15.8M 0.31%
2,633,862
+2,862
+0.1% +$22.4K
MREO
50
Mereo BioPharma
MREO
$49.1M
$15.1M 0.3%
6,710,429
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2025 Portfolio in Review

As of Q1 2025, Deerfield Management held 152 positions worth $5.06B, down 4.1% from $5.28B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $288M in Q1 2025, closing 29 positions and reducing 17 holdings. Its most notable exit was Waystar Holding Corp, an estimated $121M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate and Technology.

Against the trend, Deerfield Management opened a new position in United Therapeutics worth $84.8M.

  • Deerfield Management's largest Q1 2025 buy was United Therapeutics: 275,226 shares worth $84.8M.
  • Deerfield Management added most to Neurocrine Biosciences in Q1 2025, an estimated $79.4M increase.
  • Deerfield Management's biggest Q1 2025 reduction was Alignment Healthcare, cutting an estimated $40.8M.
  • Deerfield Management fully exited Waystar Holding Corp in Q1 2025, selling an estimated $121M.
  • Deerfield Management's ten largest holdings make up 53% of its $5.06B portfolio in Q1 2025.
  • Deerfield Management opened 45 new positions and closed 29 in Q1 2025.
  • Deerfield Management's portfolio value fell 4.1% quarter-over-quarter to $5.06B.

Based on Deerfield Management's 13F filing for Q1 2025, filed 15 May 2025.